For the quarter ended January 2025, Agilent Technologies (A) reported revenue of $1.68 billion, up 1.4% over the same period last year. EPS came in at $1.31, compared to $1.29 in the year-ago quarter.
The reported revenue represents a surprise of +0.86% over the Zacks Consensus Estimate of $1.67 billion. With the consensus EPS estimate being $1.27, the EPS surprise was +3.15%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Agilent performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue by End Markets- Pharmaceutical: $585 million versus the two-analyst average estimate of $580.91 million. The reported number represents a year-over-year change of +3.5%.
- Revenue by End Markets- Academia and Government: $137 million versus the two-analyst average estimate of $143.26 million. The reported number represents a year-over-year change of -8.7%.
- Revenue by End Markets- Environmental and Forensics: $172 million compared to the $163.03 million average estimate based on two analysts. The reported number represents a change of +3.6% year over year.
- Revenue by End Markets- Chemical and advanced materials: $379 million versus the two-analyst average estimate of $389.78 million. The reported number represents a year-over-year change of -3.3%.
- Revenue by End Markets- Food: $168 million versus $152.45 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +7% change.
- Revenue by End Markets- Diagnostics and Clinical: $240 million compared to the $237.04 million average estimate based on two analysts. The reported number represents a change of +5.3% year over year.
Shares of Agilent have returned -10.8% over the past month versus the Zacks S&P 500 composite's -2.3% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpAgilent Technologies, Inc. (A) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
